JMP Securities Maintains Market Outperform on Haemonetics, Raises Price Target to $105

JMP Securities analyst David Turkaly maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $90 to $105.

JMP Securities analyst David Turkaly maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $90 to $105.

Total
0
Shares
Related Posts